CARDINAL HEALTH INC
CAHAPI behind this page
CAH Q2 2026 request
Playground key active
/api/financials?ticker=CAH&year=2026&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Revenue | 65,627 | 55,264 | +18.8% |
Show Business Segments breakouts |
|||
| All Other Segments · at-Home Solutions [Member] | 1,185 | 835 | +41.9% |
| All Other Segments · Nuclear Precision Health Services [Member] | 440 | 372 | +18.3% |
| All Other Segments · Operating Segments | 1,724 | 1,283 | +34.4% |
| All Other Segments · OptiFreight Logistics [Member] | 99 | 76 | +30.3% |
| Cost of product sold · Operating Segments | 3,259 | 3,154 | +3.3% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 60,669 | 50,849 | +19.3% |
Show Geography breakouts |
|||
| Non Us | 435 | 428 | +1.6% |
| US | 65,217 | 54,858 | +18.9% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -25 | -22 | -13.6% |
| Operating Segments | 65,652 | 55,286 | +18.7% |
| Cost of Revenue | 63,230 | 53,323 | +18.6% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 1,291 | 969 | +33.2% |
| Cost of product sold · Operating Segments | 2,720 | 2,624 | +3.7% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 59,243 | 49,750 | +19.1% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 63,254 | 53,343 | +18.6% |
| Gross Profit | 2,397 | 1,941 | +23.5% |
| Selling, General & Administrative | 1,504 | 1,306 | +15.2% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 254 | 196 | +29.6% |
| Cost of product sold · Operating Segments | 502 | 512 | -2.0% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 739 | 568 | +30.1% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,495 | 1,276 | +17.2% |
| Restructuring Charges | 21 | 9 | +133.3% |
| Amortizationandotheracquisitionrelatedcosts | 130 | 105 | +23.8% |
| Acquisition Related Cash And Share Based Compensation Costs | 67 | — | — |
| Gain Loss On Sales Of Assets And Asset Impairment Charges | -14 | 3 | -566.7% |
| Gain Loss Related To Litigation Settlement | -18 | -31 | +41.9% |
| Operating Income | 707 | 549 | +28.8% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 179 | 118 | +51.7% |
| Cost of product sold · Operating Segments | 37 | 18 | +105.6% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 687 | 531 | +29.4% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -196 | -118 | -66.1% |
| Operating Segments | 903 | 667 | +35.4% |
| Other Non-Operating Income (Expense) | -11 | 3 | -466.7% |
| Interest Expense | 88 | 35 | +151.4% |
| Income Before Taxes | 630 | 511 | +23.3% |
| Income Tax Expense (Benefit) | 159 | 110 | +44.5% |
| Net Income | 471 | 401 | +17.5% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 4 | 1 | +300.0% |
| Net Income Loss Attributable To Noncontrolling Interest | -4 | -1 | -300.0% |
| Net Income | 467 | 400 | +16.8% |
| Income Loss From Continuing Operations Per Basic Share | 1.98 | 1.65 | +20.0% |
| Income Loss From Continuing Operations Per Diluted Share | 1.97 | 1.65 | +19.4% |
| Wtd Avg Shares (Basic) | 236 | 242 | -2.5% |
| Wtd Avg Shares (Diluted) | 237 | 243 | -2.5% |
| Common Stock Dividends Per Share Declared | 0.51 | 0.51 | +1.0% |
| Total Costs & Expenses (Q) | — | — | — |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 1,545 | 1,165 | +32.6% |
| Cost of product sold · Operating Segments | 3,222 | 3,136 | +2.7% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 59,982 | 50,318 | +19.2% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 64,749 | 54,619 | +18.5% |
| Comprehensive Income | 473 | 375 | +26.1% |
| Other Comprehensive Income | 6 | -25 | +124.0% |
Balance Sheet
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,777 | 3,810 | -27.1% |
| Receivables Net Current | 13,662 | 12,369 | +10.5% |
| Inventory | 20,116 | 16,904 | +19.0% |
| Other Assets Current | 2,675 | 2,623 | +2.0% |
| Total Current Assets | 39,230 | 35,756 | +9.7% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,877 | — | — |
Show Geography breakouts |
|||
| Non Us | 432 | — | — |
| US | 2,445 | — | — |
| Other Non-Current Assets | 1,998 | 1,252 | +59.6% |
| Total Assets | 58,083 | — | — |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 4,073 | — | — |
| Cost of product sold · Operating Segments | 6,993 | — | — |
| Pharmaceutical and Specialty Solutions · Operating Segments | 43,405 | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 1.2 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 3,612 | — | — |
| Goodwill | 11,609 | — | — |
Show Business Segments breakouts |
|||
| All Other Segments | 1,748 | — | — |
| Pharmaceutical and Specialty Solutions | 9,861 | — | — |
| Intangible Assets | 2,355 | 1,936 | +21.6% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Related Intangible Assets | 912 | — | — |
| Developed Technology Rights | 278 | 334 | -16.8% |
| Noncompete Agreements | 85 | — | — |
| Trademarks And Patents Member | 1,080 | 216 | +400.0% |
| Other Assets | |||
| Intangible Assets Net Including Goodwill | 13,978 | 7,436 | +88.0% |
| Current Liabilities | |||
| Accounts Payable | 38,996 | 31,298 | +24.6% |
| Long Term Debt And Capital Lease Obligations Current | 680 | 544 | +25.0% |
| Other Accrued Liabilities Current | 3,638 | 3,381 | +7.6% |
| Total Current Liabilities | 43,314 | 35,223 | +23.0% |
| Non-Current Liabilities | |||
| Deferred Tax And Other Liabilities Noncurrent | 9,122 | 7,638 | +19.4% |
| Total Liabilities (Q) | — | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | -960 | — | — |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 8,347 | 7,062 | +18.2% |
| Stockholders' Equity | |||
| Common Stock | 2,847 | 2,932 | -2.9% |
| Retained Earnings | 1,455 | 283 | +414.1% |
| Treasury Stock Value | -7,033 | -6,026 | -16.7% |
| Accumulated Other Comprehensive Income | -153 | -180 | +15.0% |
| Total Stockholders' Equity | -2,884 | -2,991 | +3.6% |
| Minority Interest | 184 | 70 | +162.9% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | -2,700 | -2,921 | +7.6% |
Show Equity Components breakouts |
|||
| Accumulated Foreign Currency Adjustment Including Portion Attributable To Noncontrolling Interest | -136 | -149 | +8.7% |
| Accumulated Gain Loss Net Cash Flow Hedge Noncontrolling Interest | -17 | -31 | +45.2% |
| Accumulated Other Comprehensive Income | -153 | -180 | +15.0% |
| Aoci Including Portion Attributable To Noncontrolling Interest | -153 | -180 | +15.0% |
| Common Stock | 2,847 | 2,932 | -2.9% |
| Noncontrolling Interest | 184 | 70 | +162.9% |
| Retained Earnings | 1,455 | 283 | +414.1% |
| Total Liabilities & Equity | 58,083 | 47,002 | +23.6% |
| Common Stock Shares Authorized | 755 | 755 | 0.0% |
| Common Stock Shares Issued | 271 | 271 | 0.0% |
Show Equity Components breakouts |
|||
| Common Stock | 271 | 271 | 0.0% |
| Treasury Stock Common Shares | 35 | 29 | +20.7% |
Show Equity Components breakouts |
|||
| Treasury Stock Common | 35 | 29 | +20.7% |
| Preferred Stock Shares Authorized | 500 | 500 | 0.0% |
Cash Flow Statement
| Metric | YTD Q2 2026 | YTD Q2 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 467 | 374 | +24.9% |
Show Business Segments breakouts |
|||
| All Other Segments · Operating Segments | 59 | 58 | +1.7% |
| Cost of product sold · Operating Segments | 110 | 109 | +0.9% |
| Pharmaceutical and Specialty Solutions · Operating Segments | 125 | 73 | +71.2% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 173 | 134 | +29.1% |
| Gain Loss On Sale Of Other Investments | -5 | -2 | -150.0% |
| Stock-Based Compensation | 180 | 60 | +200.0% |
| Provision For Doubtful Accounts | 27 | 28 | -3.6% |
| Increase Decrease In Receivables | -198 | -253 | +21.7% |
| Change in Inventory | -3,279 | -1,967 | -66.7% |
| Change in Accounts Payable | 4,176 | -470 | +988.5% |
| Repurchases Of Liability Classified Units | -22 | — | — |
| Increase Decrease In Other Operating Capital Net | -610 | -637 | +4.2% |
| Net Cash from Operations | 1,659 | -2,043 | +181.2% |
| Investing Activities | |||
| Payments To Acquire Businesses Net Of Cash Acquired | 1,925 | 1,076 | +78.9% |
| Capital Expenditures | -239 | -189 | -26.5% |
| Proceeds From Sale Of Property Plant And Equipment | 31 | — | — |
| Net Cash from Investing | -2,122 | -1,064 | -99.4% |
| Financing Activities | |||
| Proceeds From Issuance Of Debt | 989 | 2,869 | -65.5% |
| Repayments Of Long Term Debt | -524 | -423 | -23.9% |
| Payments To Minority Shareholders | 4 | 4 | 0.0% |
| Netproceedstaxwithholdingsfromsharebasedcompensation | -81 | -15 | -440.0% |
| Payments Of Dividends Common Stock | -251 | -250 | -0.4% |
| Share Repurchases (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Common Stock | -75 | -75 | 0.0% |
Show Share Repurchase Program breakouts |
|||
| $375 million share repurchase program | -375 | — | — |
| Share Repurchases | -758 | -390 | -94.4% |
Show Equity Components breakouts |
|||
| Treasury Stock Common | -750 | -375 | -100.0% |
| Net Cash from Financing | -629 | 1,787 | -135.2% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -5 | -3 | -66.7% |
| Net Change in Cash | -1,097 | -1,323 | +17.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,777 | 3,810 | -27.1% |
| Increase Decrease In Other Investing Items Net | 11 | 1 | +1000.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.